(Q33963199)

30 July 2017

1 reference

title

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications (English)

1 reference

30 July 2017

1 reference

Daniel B Costa

3

0 references

author name string

Hiroyuki Yasuda

series ordinal

1

1 reference

PubMed ID

21764376

30 July 2017

Susumu Kobayashi

series ordinal

2

1 reference

30 July 2017

19 July 2011

1 reference

Lancet Oncology Commission

30 July 2017

1 reference

30 July 2017

13

1 reference

30 July 2017

1

1 reference

30 July 2017

e23-31

1 reference

30 July 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

1 reference

7 January 2021

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

EGFR exon 20 insertion mutation in Japanese lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Lung cancer cell lines as tools for biomedical discovery and research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

How genetically engineered mouse tumor models provide insights into human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970129-2

7 January 2021

10.1016/S1470-2045(11)70129-2

Identifiers

DOI

1 reference

release_x3fr6oc5rngz5i7yhqagymg35a

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x3fr6oc5rngz5i7yhqagymg35a

24 November 2022

mapped directly with Wikidata item

PubMed ID

21764376

1 reference

PubMed ID

21764376